Fungal Genomics & Biology
Open Access

Amphotericin B: A Polyene Antifungal Agent

Vincent Douglas^{* *}Correspondence: Vincent Douglas, Department of Fungal Genomics and Biology, Agostinho Neto University, Luanda, Angola, Central African Republic, Email:

Author info »

Description

86 total strains, of which 10 Rhizopus spp., 47 Candida spp., and 29 Aspergillus spp. Ten Candida albicans, fifteen Candida auris, five Candida glabrata, three Candida kefyr, five Candida krusei, four Candida parapsilosis, and five Candida tropicalis made up the different Candida strains. Amphotericin B deoxycholate is an antifungal in the polyene class. It has been used to treat invasive fungal infections for more than 50 years and goes by the generic name amphotericin B as well. There are newer lipid formulations that are less harmful to the kidneys than traditional amphotericin B. In relation to the critical information required by members of an inter professional team managing the care of patients who present with mycotic infections, this activity reviews the indications, contraindications, activity, adverse events, toxicity, and other key elements of amphotericin B's antifungal uses in the clinical setting.

Uses

Following is a list of clinical features of invasive yeast and mould infections:

• Overpowering candidiasis (FDA approved). The majority of the Candida species, including Candida albicans, Candida krusei, Candida tropicalis, and Candida parapsilosis, are susceptible to its effects.
• Conventional amphotericin B is better tolerated and less harmful in neonates with candidiasis than it is in adults.
• HIV related opportunistic infections of the fungal kind can be life-threatening in both healthy and immunocompromised hosts.
• Empiric therapy in a neutropenic host with recurrent febrile episodes.
• Flucytosine and cerebral cryptococcosis for induction therapy
• Other moulds, such as Fusarium species and penicilliosis, as well as mucormycosis severe sporotrichosis cases.
• Especially in cases of severe illness, coccidioidomycosis and paracoccidioidomycosis.
• Histoplasmosis, for widespread illness.
• Blastomycosis, for a serious illness.
• Aspergillosis, for use as a last resort when voriconazole is ineffective both cutaneous and visceral leishmaniasis.

Mechanism of action

In order to work, amphotericin B binds to ergosterol in the majority of fungi's cell membrane. It stimulates the development of ion channels after interacting with ergosterol, which results in the loss of protons and monovalent cations, which causes depolarization and concentration-dependent cell death. Amphotericin B also causes oxidative damage to the cells, increasing membrane permeability and the production of free radicals. Amphotericin B also has a stimulatory impact on phagocytic cells, which aids in the removal of fungal infections. Amphotericin B has a half-life ranging from 24 hours to 15 days.

Administration

Amphotericin B is essentially insoluble in water and amphoteric (can function as both an acid and a base). It cannot be absorbed when administered orally or intramuscularly.

Amphotericin B is administered Intravenously (IV) over a period of 2 to 6 hours. Premedication 30 to 60 minutes prior to treatment with a combination of acetaminophen/ibuprofen+ diphenhydramine and/or hydrocortisone might merit consideration if the patient exhibits any of the following symptoms: Fever, hypertension, chills, or nausea. There is little evidence to support doses more than 1.5 mg/kg per day, and the risk of nephrotoxicity increases at doses higher than 1 mg/kg. Nephrotoxicity can be lessened by treating the patient with 1 litre of ordinary saline beforehand.

Although documented in the literature, amphotericin B topical usage for peritoneal or bladder cleansing is not advised. High quantities of amphotericin B are found in organs such the liver, spleen, bone marrow, kidney, and lungs. Despite having low concentrations (5% of serum) in Cerebrospinal Fluid (CSF), intrathecally administering it to treat Central Nervous System (CNS) fungi is effective (higher risk of toxicity). The reported pharmacokinetic findings in children have a substantial inter individual variability. Children appear to eliminate the medication from their bodies more quickly than adults do.

Contraindications

The past occurrence of an allergic reaction to amphotericin B is an absolute contraindication. A thorough examination of drug-drug interactions is necessary prior to any proposed administration. To lessen the risk of hypokalemia, concurrent steroid use needs to be taken into consideration. Additionally, rhabdomyolysis and digoxin toxicity can also be exacerbated by hypokalemia. Clinicians should steer clear of concurrent infusion of granulocytes and amphotericin B because they may cause acute pulmonary responses.